Stay updated with breaking news from Jacques Mallet. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
> Cash position of €17.9 million as of December 31, 2021 > Additional financing of €12 million subscribed by historical shareholders Invus and Financière de la Montagne in the form of the issuance
Dr Robert L. Coleman, Chief Scientific Officer of US Oncology Network and Dr Jacques Mallet, former SVP Portfolio Analytics/Corporate Strategy at Sanofi, join the Company's Board as independent members Regulatory
Dr Robert L. Coleman, Chief Scientific Officer of US Oncology Network and Dr Jacques Mallet, former SVP Portfolio Analytics/Corporate Strategy at Sanofi, join the Company’s Board as independent membersPARIS--(BUSINESS WIRE)--Regulatory News:Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), « Onxe...